IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stake Trimmed by Williams Jones Wealth Management LLC.

Williams Jones Wealth Management LLC. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 369,939 shares of the company’s stock after selling 24,632 shares during the quarter. IDEXX Laboratories accounts for 2.9% of Williams Jones Wealth Management LLC.’s investment portfolio, making the stock its 5th largest position. Williams Jones Wealth Management LLC. owned approximately 0.45% of IDEXX Laboratories worth $184,999,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Harbour Investments Inc. grew its stake in IDEXX Laboratories by 24.1% during the fourth quarter. Harbour Investments Inc. now owns 108 shares of the company’s stock worth $44,000 after buying an additional 21 shares during the period. RIA Advisory Group LLC grew its position in IDEXX Laboratories by 4.0% in the first quarter. RIA Advisory Group LLC now owns 572 shares of the company’s stock valued at $286,000 after acquiring an additional 22 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in IDEXX Laboratories by 10.8% in the first quarter. EverSource Wealth Advisors LLC now owns 236 shares of the company’s stock valued at $118,000 after acquiring an additional 23 shares in the last quarter. Pine Haven Investment Counsel Inc grew its position in IDEXX Laboratories by 3.2% in the first quarter. Pine Haven Investment Counsel Inc now owns 782 shares of the company’s stock valued at $391,000 after acquiring an additional 24 shares in the last quarter. Finally, IHT Wealth Management LLC grew its position in IDEXX Laboratories by 4.4% in the fourth quarter. IHT Wealth Management LLC now owns 690 shares of the company’s stock valued at $281,000 after acquiring an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 86.85% of the company’s stock.

Insider Activity

In related news, CEO Jonathan Jay Mazelsky sold 13,424 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $512.01, for a total transaction of $6,873,222.24. Following the completion of the transaction, the chief executive officer now directly owns 72,925 shares in the company, valued at approximately $37,338,329.25. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Michael Lane sold 16,027 shares of the business’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $510.00, for a total transaction of $8,173,770.00. Following the completion of the transaction, the executive vice president now owns 4,034 shares of the company’s stock, valued at $2,057,340. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 13,424 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $512.01, for a total transaction of $6,873,222.24. Following the transaction, the chief executive officer now directly owns 72,925 shares of the company’s stock, valued at approximately $37,338,329.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,360 shares of company stock valued at $26,743,411. 2.11% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on IDXX. Morgan Stanley lifted their price objective on IDEXX Laboratories from $590.00 to $600.00 and gave the stock an “overweight” rating in a report on Thursday, August 3rd. Atlantic Securities downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $610.00 price objective on the stock. in a report on Wednesday, August 2nd. StockNews.com began coverage on IDEXX Laboratories in a report on Thursday, August 17th. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $550.00 to $600.00 and gave the stock an “overweight” rating in a report on Wednesday, August 2nd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $586.00.

IDEXX Laboratories Stock Down 2.4 %

NASDAQ IDXX traded down $11.42 on Friday, hitting $465.79. 519,180 shares of the stock traded hands, compared to its average volume of 361,702. The stock has a 50-day moving average of $513.73 and a 200 day moving average of $490.97. IDEXX Laboratories, Inc. has a twelve month low of $317.06 and a twelve month high of $564.73. The company has a market capitalization of $38.66 billion, a P/E ratio of 49.45, a price-to-earnings-growth ratio of 2.77 and a beta of 1.20. The company has a current ratio of 1.33, a quick ratio of 0.89 and a debt-to-equity ratio of 0.64.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 1st. The company reported $2.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.24. IDEXX Laboratories had a return on equity of 104.84% and a net margin of 22.52%. The firm had revenue of $943.63 million for the quarter, compared to analysts’ expectations of $927.84 million. As a group, analysts expect that IDEXX Laboratories, Inc. will post 9.82 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.